M. Nagel

发表

Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2021, Clinical and translational gastroenterology.

Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.

P. Galle, You-Wen He, J. Schattenberg, 2011, Journal of hepatology.

Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis

J. Schattenberg, C. Labenz, M. Wörns, 2022, Diagnostics.

Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2021, Scientific Reports.

Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives

P. Galle, J. Schattenberg, C. Labenz, 2020, Health and Quality of Life Outcomes.

Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.

P. Galle, J. Schattenberg, C. Labenz, 2020, European journal of internal medicine.

Diabetic liver injury from streptozotocin is regulated through the caspase-8 homolog cFLIP involving activation of JNK2 and intrahepatic immunocompetent cells

P. Galle, J. Schattenberg, T. Kohl, 2013, Cell Death and Disease.

Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.

P. Galle, J. Schattenberg, M. Schuchmann, 2018, American journal of physiology. Gastrointestinal and liver physiology.

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

J. Schattenberg, C. Labenz, J. Marquardt, 2020, Zeitschrift für Gastroenterologie.

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy.

P. Galle, J. Schattenberg, C. Labenz, 2019, European journal of internal medicine.

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2019, The American journal of gastroenterology.

Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany

P. Galle, J. Schattenberg, K. Kostev, 2019, Digestive Diseases and Sciences.

Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)

A. Grambihler, J. Schattenberg, C. Labenz, 2019, Zeitschrift für Gastroenterologie.

Characteristics of bacterial infections and prevalence of multidrug-resistant bacteria in hospitalized patients with liver cirrhosis in Germany.

J. Schattenberg, C. Labenz, E. Siegel, 2022, Annals of hepatology.

Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care

P. Galle, J. Schattenberg, C. Labenz, 2021, PloS one.

Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP.

D. Schuppan, P. Galle, You-Wen He, 2012, American journal of physiology. Gastrointestinal and liver physiology.

Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2

P. Galle, C. Labenz, J. Marquardt, 2019, United European gastroenterology journal.

P. Galle, A. Grambihler, J. Schattenberg, 2021, Quality of Life Research.

Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol

P. Galle, P. Wild, J. Schattenberg, 2019, Hepatology communications.

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression

P. Galle, J. Schattenberg, K. Kostev, 2020, Hepatology communications.

Hepatische Manifestation eines Makrophagen-Aktivierungs-Syndroms (MAS)

P. Galle, A. Schwarting, B. Straub, 2017, Zeitschrift für Gastroenterologie.

Risk factors for poorer health literacy in patients with liver cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2021, PloS one.

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients

P. Galle, J. Schattenberg, C. Labenz, 2018, Alimentary pharmacology & therapeutics.

Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany

D. Schuppan, P. Galle, J. Schattenberg, 2018, Alimentary pharmacology & therapeutics.

P. Galle, J. Schattenberg, C. Labenz, 2019, European journal of internal medicine.

Continued alcohol consumption and hepatic encephalopathy determine quality of life and psychosocial burden of caregivers in patients with liver cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2022, Health and Quality of Life Outcomes.

Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.

P. Galle, J. Schattenberg, C. Labenz, 2022, Clinics and research in hepatology and gastroenterology.

Evaluation of IL‐6 for Stepwise Diagnosis of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2022, Hepatology communications.

Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

P. Galle, J. Schattenberg, C. Labenz, 2019, Alimentary pharmacology & therapeutics.

Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis

J. Schattenberg, C. Labenz, S. Bittner, 2023, JHEP reports : innovation in hepatology.

Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis

P. Galle, C. Labenz, M. Wörns, 2020, Clinical and translational gastroenterology.

Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2020, Alimentary pharmacology & therapeutics.

Frailty as Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver Cirrhosis

J. Schattenberg, C. Labenz, M. Wörns, 2022, Clinical and translational gastroenterology.

Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.

F. Lammert, C. Labenz, M. Wörns, 2022, Journal of hepatology.

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

P. Galle, J. Schattenberg, S. Al-Batran, 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC)

A. Grambihler, J. Schattenberg, C. Labenz, 2019, Digestive Diseases and Sciences.

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy

P. Galle, C. Labenz, J. Marquardt, 2019, Journal of clinical gastroenterology.